These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15364552)

  • 21. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry.
    Machecourt J; Danchin N; Lablanche JM; Fauvel JM; Bonnet JL; Marliere S; Foote A; Quesada JL; Eltchaninoff H; Vanzetto G;
    J Am Coll Cardiol; 2007 Aug; 50(6):501-8. PubMed ID: 17678732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent.
    Ahmed WH
    Expert Rev Med Devices; 2007 Mar; 4(2):117-20. PubMed ID: 17359218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local vascular toxicokinetics of stent-based drug delivery.
    Tesfamariam B
    Toxicol Lett; 2007 Jan; 168(2):93-102. PubMed ID: 17169513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis.
    Takemoto Y; Kawata H; Soeda T; Imagawa K; Somekawa S; Takeda Y; Uemura S; Matsumoto M; Fujimura Y; Jo J; Kimura Y; Tabata Y; Saito Y
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):857-62. PubMed ID: 19325141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
    Vaina S; Ong AT; Serruys PW
    Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nitric oxide: implications for vascular and endovascular surgery.
    Vural KM; Bayazit M
    Eur J Vasc Endovasc Surg; 2001 Oct; 22(4):285-93. PubMed ID: 11563885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Very late drug-eluting stent thrombosis and cardiogenic shock: 1,249 days after implantation.
    Chen JP
    J Invasive Cardiol; 2007 Dec; 19(12):E381-4. PubMed ID: 18180534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
    Kohn J; Zeltinger J
    Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare-metal versus paclitaxel-eluting stents.
    Cho HJ; Kim TY; Cho HJ; Park KW; Zhang SY; Kim JH; Kim SH; Hahn JY; Kang HJ; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Jul; 48(2):366-74. PubMed ID: 16843188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronary small-vessel stenting in the era of drug elution.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 2():S34-45. PubMed ID: 15184832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel-eluting balloon: from bench to bed.
    De Labriolle A; Pakala R; Bonello L; Lemesle G; Scheinowitz M; Waksman R
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):643-52. PubMed ID: 19309715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time dependent vascular and myocardial responses of a second generation, small vessel, paclitaxel-eluting stent platform.
    Thompson CA; Huibregtse B; Poff B; Wilson GJ
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):597-604. PubMed ID: 19180652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.
    Kavanagh CA; Rochev YA; Gallagher WM; Dawson KA; Keenan AK
    Pharmacol Ther; 2004 Apr; 102(1):1-15. PubMed ID: 15056495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-eluting stents: a pharmacoclinical perspective.
    Thomas MK; Gupta YK
    Natl Med J India; 2006; 19(4):195-9. PubMed ID: 17100106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suprarenal stents and other advances in endovascular aneurysm repair.
    Chuter TA; Howell BA
    Surg Clin North Am; 2004 Oct; 84(5):1319-35, vii. PubMed ID: 15364557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Past, present and future of femoropopliteal stenting.
    Schillinger M; Minar E
    J Endovasc Ther; 2009 Feb; 16 Suppl 1():I147-52. PubMed ID: 19317587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental efficacy of an everolimus eluting cobalt chromium stent.
    Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endovascular therapy for upper extremity injury.
    Ohki T; Veith FJ; Kraas C; Latz E; Gitlitz D; Quintos RT; Sanchez LA
    Semin Vasc Surg; 1998 Jun; 11(2):106-15. PubMed ID: 9671240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-eluting stents: beyond the hyperbole.
    Hunter WL
    Adv Drug Deliv Rev; 2006 Jun; 58(3):347-9. PubMed ID: 16600419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical use of sirolimus-eluting stents.
    Kirtane AJ; Leon MB
    Cardiovasc Drug Rev; 2007; 25(4):316-32. PubMed ID: 18078432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.